Clexane after hemorrhagic stroke
Reading File
Finding Sources
Finding Sources
Searching PubMed
enoxaparin "intracerebral hemorrhage" venous thromboembolism prophylaxis
Searching the Web
Clexane enoxaparin timing after hemorrhagic stroke DVT prophylaxis guidelines 2024
Finding Sources
Searching PubMed
"intracerebral hemorrhage" AND "heparin" AND "thromboprophylaxis"
Reading File
Reading File
Reading Article
Reading Article
Reading File
Finding Sources
I now have comprehensive information to give a thorough, evidence-based answer. Here is the synthesis:
Clexane (Enoxaparin) After Hemorrhagic Stroke
The Core Clinical Dilemma
Patients with intracerebral hemorrhage (ICH) face two competing risks:
- Hematoma expansion / rebleeding if anticoagulation is used
- Venous thromboembolism (VTE) — DVT occurs in up to ~15% of untreated immobile ICH patients; PE can be fatal
1. Acute Phase (first 24–48 h): LMWH is Contraindicated
Anticoagulation is not indicated in the acute period after spontaneous ICH. The priority is:
- Reversing any pre-existing anticoagulation
- Controlling blood pressure
- Preventing early hematoma expansion
The only exception is cerebral venous sinus thrombosis (CVST) as the cause of the hemorrhage — in this case, IV heparin or LMWH should be started even with ICH present, as the underlying thrombosis must be treated.
2. VTE Prophylaxis in Stable ICH Patients
Mechanical (always first-line)
Pneumatic compression devices (PCDs) are recommended immediately for all immobile ICH patients, as they reduce DVT risk without bleeding risk. — Goldman-Cecil Medicine, 26th ed.
Pharmacological (LMWH / Clexane)
"Low-molecular-weight heparin can be safely administered to stable patients" with ICH who are at risk of DVT. — Goldman-Cecil Medicine
Key evidence on timing and safety:
| Meta-analysis | Finding |
|---|---|
| Chi et al., Thromb Haemost 2022 (n=3,697, 28 studies) [PMID 35717948] | Thromboprophylaxis with heparins ↓ DVT by 76% (RR 0.24) and PE by 67% (RR 0.33) vs. control, with no increase in hematoma expansion or rebleeding (RR 0.75, 95% CI 0.48–1.18) |
| Salvagni et al., Neurosurg Rev 2024 (PMID 39090364) | Ultra-early (<24 h) or early (<48 h) vs. late (>48 h) thromboprophylaxis showed no difference in hematoma expansion (OR 0.94) or mortality. Suggests early initiation may be safe. |
Standard clinical practice: Initiate LMWH prophylaxis at 48–72 hours after documented hemorrhage stability (confirmed on repeat imaging), in patients who are:
- Hemodynamically stable
- Not requiring further surgical intervention
- Without coagulopathy
Typical dosing: Enoxaparin 40 mg SC once daily (standard prophylactic dose), adjusted for renal function (GFR <30: use UFH or dose-reduce).
3. Special Scenario: Pre-existing Indication for Full Anticoagulation
If the patient had an indication for therapeutic anticoagulation (e.g., AF, mechanical valve, prior DVT/PE) before the ICH:
- Withhold anticoagulation acutely
- Reassess at 4–8 weeks with repeat imaging
- Re-initiation of anticoagulation requires multidisciplinary neurology/cardiology shared decision-making
- Benefit of stroke prevention in high-risk AF (CHA₂DS₂-VASc ≥4) often outweighs rebleeding risk after the acute period
- DOACs (rivaroxaban, apixaban) are preferred over warfarin for AF, given their lower ICH risk
4. Antiplatelet Agents After ICH
Antiplatelet agents are generally withheld in the acute period. Resumption (if there was a prior indication, e.g., secondary ischemic stroke prevention) can be considered after 1–4 weeks depending on hematoma stability and underlying cause (avoid resumption if cerebral amyloid angiopathy is suspected).
Summary Table
| Timeframe | Clexane Use | Notes |
|---|---|---|
| 0–24 h | Contraindicated (except CVST) | Risk of hematoma expansion |
| 24–48 h | Borderline — use PCDs | Emerging data supports safety but not yet standard |
| 48–72 h | Prophylactic dose acceptable if hematoma stable | Confirm stability with repeat CT; use PCDs in parallel |
| >1 week | Therapeutic dose if prior indication | Shared decision-making; prefer DOAC over warfarin for AF |
Sources:
- Goldman-Cecil Medicine, 26th ed. (ICH management section)
- Barash's Clinical Anesthesia, 9th ed.
- Chi G et al. Systematic Review and Meta-Analysis of Thromboprophylaxis with Heparins Following ICH. Thromb Haemost 2022 [PMID 35717948]
- Salvagni FP et al. Timing of Thromboprophylaxis Following Spontaneous ICH. Neurosurg Rev 2024 [PMID 39090364]
This is a shared conversation. Sign in to Orris to start your own chat.